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suggesting that increased collagen binding was a characteristic of
polycystic cells rather than being a nonspecific effect of immor-
talization.
These results suggested that a specific receptor for extracellular
matrix proteins was activated or overexpressed in polycystic cells.
Data suggested that this collagenilaminin receptor was an inte-
grin. Beta-i integrins are widely expressed and are known to be
expressed in kidney epithelial cells. Therefore, if an integrin was
responsible for the adhesion of polycystic cells, it was likely to be
a beta-i integrin. An antibody to the extracellular domain of the
beta-i integrin subunit completely inhibited binding to collagen,
confirming that the integrin involved in collagen adhesion is
beta-i. Immunoprecipitation confirmed this finding and showed
that the major alpha subunit associated with the beta-i integrin
was alpha-i. Preliminary studies suggest that the number of cell
surface integrins is the same in normal and polycystic cells, despite
the two- to fivefold difference in collagen adhesion. These results
suggest that either the affinity of the integrin for collagen is
increased in polycystic cells or that the differences in adhesion are
due to cellular events involving not the initial adhesive event but
the subsequent strengthening of adhesion. Strengthening of the
initial adhesive event is well known to occur in a process that may
involve the cytoskeleton. The latter possibility is particularly
interesting in the light of the recent observation that taxol, a
microtubule stabilizing agent, prevents cyst formation in vitro and
progression of renal cystic disease in cpk mice in vivo.
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Changes in fibroblast growth and extracellular matrix
metabolism in ADPKD
J. Norman, N-T Kuo, L. Gatti, C. Orphanides, and P.D. Wilson
The Rayne Institute, University College London Medical School, London,
England, United Kingdom
In ADPKD, cyst development and expansion is accompanied by
progressive fibrosis of the tubulointerstitium with widening of the
tubular basement membrane, some increase in interstitial cell
number and accumulation of extracellular matrix (ECM) within
the interstitium. Disease prognosis in a number of progressive
renal diseases, including ADPKD, correlates closely with the
degree of involvement of the interstitium. This has directed
attention to understanding the biology of the cells within the
interstitium, particularly the interstitial fibroblasts.
Cultures of interstitial fibroblasts from normal and ADPKD
human kidneys can be established in vitro. Normal and ADPKD
fibroblasts exhibit different morphologies in vitro and show differ-
ent growth characteristics, with ADPKD cells having an increased
proliferative capacity. Furthermore, fibroblasts derived from end-
stage ADPKD kidneys form colonies in soft agar. However,
ADPKD fibroblasts have a finite lifespan in vitro, suggesting that
these cells are not transformed.
The increased proliferative capacity of ADPKD fibroblasts is
consistent with altered responsiveness to growth factors and/or
the production of autocrine factors. Comparison of the mitogenic
effect of a range of growth factors (EGF, PDGF, TGF-a and -f3,
acidic FGF, IGF I and II) revealed differences in the proliferative
response in normal and ADPKD fibroblasts; in particular, aFGF
is a more potent mitogen for ADPKD cells compared to their
normal counterparts. ADPKD fibroblasts produce and secrete
more aFGF than normal fibroblasts. Both cell types have high and
low affinity receptors for aFGF, and there is no apparent change
in the affinity for the high affinity (signal transducing) receptor in
ADPKD and normal fibroblasts. However, Western blotting of
homogenates from aFGF-stimulated cells using an anti-phospho-
tyrosine antibody suggests differences in the proteins phosphory-
lated following receptor-ligand interaction in the two cell types.
Taken together, these data suggest that the increased proliferative
capacity of ADPKD fibroblasts may be mediated, at least in part,
by an autocrine loop involving aFGF. Tissue homogenates from
ADPKD kidneys also contain higher levels of aFGF than from
normal kidneys. Immunostaining of tissue sections shows in-
creased immunoreactivity for aFGF in the ECM of ADPKD
kidneys, suggesting that this factor may have some in vivo
relevance in the fibrotic response associated with ADPKD. It is,
however, unlikely that a single factor is responsible for the
changes in interstitial fibroblast function in fibrosis and the role of
other factors is being investigated. ADPKD fibroblasts appear to
produce more TGF-/3. While the ubiquitous distribution and
multifunctional nature of this factor requires that such observa-
tions be interpreted with caution, TGF-f3 has been advocated as a
major fibrogenic factor in a variety of pathological disorders.
Although there is some increase in interstitial cell number in
fibrosis, the most striking aspect of the response is the accumu-
lation of ECM, Changes in the type and amount of matrix to
which the cells are exposed is likely to have profound repercus-
sions on cellular function and on the interaction between different
cell types. By immunostaining there is some increase in the
amount of collagens (types I, III and IV) and fibronectin within
the interstitium. In addition, tenascin shows abnormal localization
with focal expression in ADPKD.
Accumulation of ECM can occur as a result as a result of
increased synthesis, decreased degradation or some combination
of these processes. Northern blot analysis of levels of mRNAs
for various matrix proteins show increased expression of these
mRNAs, suggesting that an increase in synthesis contributes to
the accumulation of ECM. However, these analyses cannot dis-
tinguish between increased gene transcription and increased
stability of mRNA.
Turnover (degradation) of the ECM is tightly controlled and
regulated primarily by a group of enzymes known as the matrix
metalloproteinases (MMPs). The activity of MMPs is inhibited by
tissue inhibitors of metalloproteinases (TIMP5). Decreased deg-
radations of ECM may be due to decreased enzyme production or
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activity or increased production of inhibitors. Immunostaining of
sections of normal and ADPKD kidneys with antibodies to MMPs
and TIMP-1, showed predominantly tubular staining. Normal
tubular epithelia produce gelatinases A (GA) and B (GB) and
TIMP and express low levels of stromelysin (SL). An increase in
MMP expression in early ADPKD correlated with expanding
cysts; TIMP expression is also markedly increased in ADPKD
kidneys. In end-stage disease MMP expression declined, but
TIMP levels remained elevated. In vitro, ADPKD fibroblasts
expressed increased GA, SL and TIMP compared to normal cells.
The increase in TIMP in both epithelial cells and fibroblasts
appeared to be mediated by an increase in gene transcription.
Gelatin-substrate zymography showed that epithelial cells pro-
duce both active and inactive GA but only the inactive GB, while
fibroblasts secrete predominantly the inactive gelatinase A. These
data suggest that matrix accumulation occurs as a result of an
imbalance between proteolytic enzyme and inhibitor production
exacerbated by an increase in synthesis of matrix components.
In conclusion, the accumulation of ECM in ADPKD involves
changes in interstitial cell proliferation and alterations in matrix
synthesis, composition and degradation. Fibrosis is a significant
feature of ADPKD contributing to the progressive nature of the
disease. An understanding of the mechanisms regulating the
increased synthesis and decreased breakdown of the ECM may
identify molecular targets for therapeutic intervention to retard or
reverse the process.
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IV: THE ETIOLOGY OF HEREDITARY POLYCYSTIC
DISORDERS: PROGRESS IN CLONING DISEASE GENES
The genome project: Implications for genetic renal medicine
R. Worton
Hospital for Sick Children, Toronto, Canada
The international Human Genome Project (HGP) is now into
its fourth year. The goal is to develop a map of the human genome
and to ultimately determine the sequence of bases for each of the
human chromosome. This will reveal all of the genes in
the genome, and their nucleotide sequence will be used to predict
the amino acid sequence of the encoded proteins. Having a
catalogue of the genes and gene products will greatly simplify the
process of identifying genes associated with genetically deter-
mined disease. An example of a typical scenario is based on my
own work with the gene that causes Duchenne muscular dystro-
phy. It was possible to clone and sequence this gene before the
genome project began because of a few affected individuals with
chromosomal translocations that disrupt the gene. These rear-
rangements of the X chromosome always involved a break in the
middle of the short arm at band Xp21 indicating the presence of
a critical gene at this map location. Cloning of DNA from this
region of the X chromosome led to the identification of the gene
responsible for the disease. Expression of the gene in bacteria
gave a protein product that was used to raise antibodies in rabbits,
and these were used to determine the location of the protein (now
called dystrophin) at the inner surface of the muscle cell mem-
brane. Sequencing of the gene showed that dystrophin resembles
several cytoskeletal proteins, including a spectrin-like rod region
in the middle, and actin-binding domain at the N-terminal end
and a C-terminal end that binds to a transmembrane glycoprotein
complex that connects to laminin in the extracellular matrix. Thus,
dystrophin is thought to provide stability to the muscle membrane,
and in affected boys with little or no functional dystrophin the
membrane is susceptible to contraction-induced tearing and mus-
cle degeneration. Knowledge of the gene provides probes for
diagnostic testing, which has been used routinely since 1988 to
identify carriers of the defective genes and for prenatal detection
of gene defects in the developing fetus. Selective termination of
pregnancy allows families with one affected child to choose not to
have further affected children.
The genome project is making this type of information available
for a great number of genetic diseases, including renal diseases,
and also for diseases that are not strictly inherited but neverthe-
less have a genetic component. This would include such common
disorders as diabetes, asthma, hypertension, cardiovascular dis-
ease, etc., in which familial tendencies suggest an underlying
genetic basis, and diseases like cancer where genes that start out
normal accumulate mutations in the cells of the body until
activation of an oncogene or loss of a tumor-suppressor gene
results in a cell that has lost its growth control. As more and more
genes are cloned and identified, the availability of genetic testing
will spread into every branch of medicine. Genetic testing tech-
nology also moves ahead with cheaper and faster tests based on
the polymerase chain reaction (PCR) replacing the more difficult
Southern blotting technology, and with manual approaches being
replaced with automated "gene readers". A dramatic example of
extensive genetic testing is the near-complete eradication of
thalassemia in Cyprus by genetic screening of child-bearing
couples by prenatal diagnosis and selective pregnancy termina-
tion.
While diagnostic testing follows quickly and easily from the
cloning of a disease gene, finding a cure is another matter entirely.
Most would agree that understanding of the basic defect through
gene cloning is a fundamental step on the way to effective therapy,
but it is certainly no guarantee of success, In most cases one can
anticipate several years between cloning of a gene and a full
understanding of the disease pathology. Even then it may not be
apparent how to go about replacement of the altered gene
product or therapeutic intervention that bypasses the need for the
gene product. During this period of simple and effective diagnos-
tic tests with no effective treatment, there emerge several social,
ethical and legal issues. One is defining what qualifies as a genetic
disease, as distinct from a genetic trait. Another is determining
the correct balance between protecting of the rights of an
individual to keep his/her genetic information private, and the
need to inform family members at risk for genetic disease
